U.S. pharma large copyright scrapped two experimental weight loss capsules previous year—a the moment-day-to-day tablet, lotiglipron, resulting from elevated liver enzymes along with a two times-day by day tablet, danuglipron, because of strong side effects—but CEO Albert Bourla has